More than half of drug companies plan to increase spending for market-access activities in 2012, including comparative effectiveness research (CER), according to a report from Cutting Edge Information.
Responding to payer demands for outcomes, virtually all drug research companies expect to at least maintain spend across most market-access categories, the benchmarking study showed.
Growth areas include health economics and outcomes research (64% of firms plan to increase funding), as well as patient-reported-outcomes activities, pegged by 57% of respondents for more spend, and CER, which half of firms anticipate upping their spend for.
Across all market access activities studied, pricing teams' budgets will largely remain the same. And according to the study, 73% of companies will hold their pricing budgets steady next year.
Cutting Edge talked to 20 companies for its study, said Elio Evangelista, director of research for the firm.